Granules Life Sciences (GLS) has marked a significant milestone with its manufacturing facility located in Shamirpet, near Hyderabad, receiving a Voluntary Action Indicated (VAI) classification from the U.S. Food and Drug Administration (FDA). This development stems from a thorough inspection conducted from December 15 to 19, 2025, focusing on the company’s oral solid dosage manufacturing operations. The establishment inspection report (EIR) confirms that the inspection has concluded with no regulatory actions recommended, enhancing the company’s standing in the pharmaceutical manufacturing sector.
Strengthening Manufacturing Capabilities
This VAI classification is a considerable asset for Granules India, bolstering its capacity for finished dosage manufacturing. The approval facilitates multi-site manufacturing of products, a strategic move that aligns with the company’s growth objectives and enhances operational flexibility. The classification not only affirms the quality of manufacturing practices but also opens doors to future partnerships and expanded market opportunities.
Insights from the Inspection
During the December inspection, the FDA issued five observations related to procedural requirements. Importantly, none of these observations pertained to data integrity or product safety, which are critical factors in pharmaceutical manufacturing. This positive outcome underscores Granules Life Sciences’ commitment to adhering to stringent industry standards, a commitment that is vital for maintaining trust with regulatory bodies and customers alike.
Commitment to Quality
Krishna Prasad Chigurupati, the Chairman and Managing Director of Granules India, emphasized the company’s ongoing dedication to quality. He remarked that while receiving the VAI classification is a step in the right direction, quality assurance must be viewed as an ongoing commitment rather than a one-time achievement. This philosophy is embedded in the culture of Granules Life Sciences and remains a core principle across all its facilities.
Understanding VAI Classification
The FDA utilizes a tiered classification system in its EIR, which includes VAI, No Action Indicated (NAI), and Official Action Indicated (OAI). The VAI classification signifies that while some objectionable conditions or practices were noted, the FDA does not intend to pursue administrative or regulatory actions. In contrast, an NAI classification indicates no issues were found, while an OAI classification suggests that regulatory actions are warranted due to significant findings.
Future Prospects
With the VAI classification now in hand, Granules Life Sciences is well-positioned for future growth. The ability to manufacture approved products across multiple sites enhances operational efficiency and supports the company’s strategic goals. This achievement not only reflects the company’s robust manufacturing framework but also its adaptability in a rapidly evolving industry.
Key Takeaways
- Granules Life Sciences received VAI classification from the U.S. FDA for its Hyderabad facility.
- The inspection concluded with five procedural observations, but no issues related to data integrity or product safety.
-
The VAI classification strengthens multi-site manufacturing capabilities for approved products.
-
Quality assurance remains a fundamental commitment for Granules Life Sciences, according to CMD Krishna Prasad Chigurupati.
-
The classification is part of a tiered FDA system, indicating varying levels of compliance.
In conclusion, Granules Life Sciences’ successful navigation of the FDA inspection process and its attainment of VAI classification reflect a robust commitment to quality and operational excellence. This achievement not only enhances its manufacturing capabilities but also sets the stage for future growth and innovation in the pharmaceutical landscape. With quality as a continuous goal, Granules Life Sciences is prepared to tackle new challenges and seize emerging opportunities in the market.
Read more → www.thehindu.com